BofA raised the firm’s price target on Alkermes to $29 from $27 and keeps a Neutral rating on the shares. The target raise reflects the inclusion of $92M in cash proceeds from the company’s sale of a manufacturing facility to Novo and a change in valuation methodology from current discounted cash flow to now a blended mix of DCF and price-to-earnings, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALKS:
- Alkermes, Armstrong World, National Healthcare, PJT Partners to join S&P 600
- Alkermes to sell manufacturing facility in Ireland to Novo Nordisk for $92.5M
- Alkermes weakness on Jazz pause a buying opportunity, says Mizuho
- Alkermes reinstated with a Neutral at JPMorgan
- Alkermes raises FY23 adjusted EPS view to $1.57-$1.75 from $1.34-$1.57